ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1873

Relationship Between Baseline Characteristics of Rheumatoid Arthritis and Types of Mortality: Study of Cohort Followed Prospectively

Cristina Corrales1, Fabricio Benavides Villanueva1, Ivan Ferraz Amaro2, Nuria Vegas Revenga3, Virgi Portilla4, Ricardo Blanco5, Miguel Ángel González-Gay6 and Alfonso Corrales4, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, 3Hospital Galdakao- Usansolo, Galdakao, Spain, 4Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 5Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 6Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Meeting: ACR Convergence 2022

Keywords: Biomarkers, Comorbidity, Mortality, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: Muscle Biology, Myositis and Myopathies Poster II

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of mortality mainly due to cardiovascular (CV) events, infections and malignancies. The relationship between the characteristics of the disease at the baseline and the different types of mortality is not well established in RA. The main objective of this abstract is to establish the characteristics related to the disease that could be predictors of the most frequent types of mortality in patients with RA.

Methods: We conducted a prospective longitudinal study of 673 patients with RA in a single tertiary center. The different types of mortality and their association with patient- and disease-dependent factors were analyzed using multivariate Cox regression.

Results: We included 673 patients with RA, women (75%), mean age 61±13 years. The main baseline characteristics, CV risk factors, activity data, and treatments are detailed in Table 1.

After a follow-up of 4367 person-year (mean time 6.4±1.4 years), 67 deaths were observed. The causes of death in order of frequency were: infections (N=23) (34%), malignancies (N=18) (27%), CV events (N=12) (18%), lung disease (N=2) (3%), and others (N=12) (18%). The main results of the study are summarized in Table 2. In relation to mortality due to infections, arterial hypertension (HR 4.43 (1.64-11.94), p=0.003) and Diabetes Mellitus (DM) (HR 3.87 (1.65-9.17), p=0.002) showed a statistically significant association in the univariate analysis. In the multivariate regression analysis adjusted for CV risk factors, the characteristics of the disease that presented statistical significance were the presence of RF (HR 3.18 (1.24-8.14), p=0.016) and ACPA (HR 2.95 (1.19-7.33). ), p=0.020), high values of CRP (HR 1.03 (1.02-1.05), p < 0.001), DAS28-ESR (HR 1.53 (1.10-2.13), p=0.012) and DAS28-CRP (HR 1.66 (1.16 -2.37), p= 0.006), as well as Prednisone treatment (HR 2.73 (1.01-7.42), p=0.048) and Rituximab (HR 8.76 (2.39-32.08), p=0.001). In mortality due to malignancies, only the male gender (HR 3.12 (1.24-7.87), p = 0.016), abdominal circumference (HR 1.05 (1.03-1.09), p < 0.001) and DM (HR 3.56 (1.33-9.48), p=0.011) showed statistical significance. However, none of the disease-related factors were statistically associated with cancer mortality. In relation with CV mortality, only arterial hypertension (HR 3.90 (1.05-14.43), p=0.04) presented a statistically significant association in the univariate analysis. In multivariate analysis adjusted for CV risk factors, disease-related factors associated with CV mortality were elevated ESR (HR 1.04 (1.02-1.06), < 0.001) and DAS28-ESR (HR 1.79 (1.13- 2.82), p=0.012) and NSAIDs treatment (HR 5.48 (1.46-20.53), p=0.012).

Conclusion: Factors related to disease activity and different types of therapy at baseline were associated with mortality from CV events and infections in RA patients.

Supporting image 1

Table 1. Baseline characteristics of 673 RA patients.

Supporting image 2

Table 2. Multivariate analysis adjusted for age, sex and those CV risk factors that showed a statistically significant association in the univariate analysis. In bold, statistically significant results (HR, p<0.05)


Disclosures: C. Corrales, None; F. Benavides Villanueva, None; I. Ferraz Amaro, AbbVie/Abbott, Merck/MSD, Janssen, Roche, AbbVie/Abbott, Pfizer, Roche, Amgen, Celgene, Merck/MSD; N. Vegas Revenga, None; V. Portilla, None; R. Blanco, Eli Lilly, Pfizer, Roche, Janssen, MSD, AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Galapagos, Novartis, Sanofi; M. González-Gay, AbbVie/Abbott, Merck/MSD, Janssen, Roche, AbbVie/Abbott, Roche, Sanofi, Eli Lilly, Celgene, Sobi, Merck/MSD; A. Corrales, None.

To cite this abstract in AMA style:

Corrales C, Benavides Villanueva F, Ferraz Amaro I, Vegas Revenga N, Portilla V, Blanco R, González-Gay M, Corrales A. Relationship Between Baseline Characteristics of Rheumatoid Arthritis and Types of Mortality: Study of Cohort Followed Prospectively [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/relationship-between-baseline-characteristics-of-rheumatoid-arthritis-and-types-of-mortality-study-of-cohort-followed-prospectively/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/relationship-between-baseline-characteristics-of-rheumatoid-arthritis-and-types-of-mortality-study-of-cohort-followed-prospectively/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology